Fig. 2

BRCA-LOF by epigenetic or genetic aberrations and survival. (A) Analysis of progression-free survival (PFS) and (B) overall survival (OS). Subgroup analyses of HRD-positive BRCA-wt-unmeth HGOC for (C) PFS and (D) OS compared with HRD-negative BRCA-wt-unmeth and with BRCA-LOF HGOC and for (E) PFS and (F) OS compared with the entire HRD-negative cohort